Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
企業コードMANE
会社名Veradermics Inc
上場日Feb 04, 2026
最高経営責任者「CEO」Waldman (Reid Alexander)
従業員数19
証券種類Ordinary Share
決算期末Feb 04
本社所在地- -
都市- -
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コードMANE
上場日Feb 04, 2026
最高経営責任者「CEO」Waldman (Reid Alexander)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし